The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
The immune system and inflammation in breast cancer
Open accessAbstract
During different stages of tumor development the immune system can either identify and destroy tumors, or promote their growth. Therapies targeting the immune system have emerged as a promising treatment modality for breast cancer, and immunotherapeutic strategies are being examined in preclinical and clinical models. However, our understanding of the complex interplay between cells of the immune system and breast cancer cells is incomplete. In this article, we review recent findings showing how the immune system plays dual host-protective and tumor-promoting roles in breast cancer initiation and progression. We then discuss estrogen receptor α (ERα)-dependent and ERα-independent mechanisms that shield breast cancers from immunosurveillance and enable breast cancer cells to evade immune cell induced apoptosis and produce an immunosuppressive tumor microenvironment. Finally, we discuss protumorigenic inflammation that is induced during tumor progression and therapy, and how inflammation promotes more aggressive phenotypes in ERα positive breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 2×
“Overproduction of the enzyme IDO by cancer cells suppresses CD8+ T cell activity (Uyttenhove et al., 2003), and IDO inhibition potentiates responses of breast cancer to chemotherapy (Muller et al., 2005).”
BackgroundColony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085 · cited 1×
“Disruption of the CXCL1/2-S100A8/9 axis by CXCR2 inhibition increases the effectiveness of chemotherapy (Acharyya et al., 2012).”
BackgroundMuller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
Tumor-Associated Macrophages Press the Angiogenic Switch in Breast Cancer
Lin, E. Y., & Pollard, J. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0912 · Cited by 463
Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M. (2007) · The FASEB Journal · doi:10.1096/fj.07-8832com · Cited by 222 · cited 1×
“For instances, IL-6 promotes proliferation as well as aggressive phenotype of ERα+ breast cancer cells (Sasser et al., 2007, Sullivan et al., 2009); IL-1β reverses the suppression of estrogen target genes by SERM (Zhu et al., 2006), suggesting IL-1β may be directly associated with resistance to…”
BackgroundOestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2
Wang, X., Belguise, K., Kersual, N., Kirsch, K. H., Mineva, N. D., Galtier, F., Chalbos, D., & Sonenshein, G. E. (2007) · Nature Cell Biology · doi:10.1038/ncb1559 · Cited by 209
Cited by
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Self-citationRole of the Tumor Microenvironment in Breast Cancer
Soysal, S. D., Tzankov, A., & Muenst, S. E. (2015) · Pathobiology · doi:10.1159/000430499 · Cited by 510
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
The integration of inflammaging in age-related diseases
Fulop, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 348
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Established breast cancer risk factors and risk of intrinsic tumor subtypes
Barnard, M. E., Boeke, C. E., & Tamimi, R. M. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.002 · Cited by 278
Beneficial bacteria inhibit cachexia
Varian, B. J., Goureshetti, S., Poutahidis, T., Lakritz, J. R., Levkovich, T., Kwok, C., Teliousis, K., Ibrahim, Y. M., Mirabal, S., & Erdman, S. E. (2016) · Oncotarget · doi:10.18632/oncotarget.7730 · Cited by 146
Witek Janusek, L., Tell, D., & Mathews, H. L. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.04.012 · Cited by 143
Identifying and analyzing different cancer subtypes using RNA-seq data of blood platelets
Zhang, Y.-H., Huang, T., Chen, L., Xu, Y., Hu, Y., Hu, L.-D., Cai, Y., & Kong, X. (2017) · Oncotarget · doi:10.18632/oncotarget.20903 · Cited by 54
Metadata
- Authors
- Jiang, X., & Shapiro, D. J.
- Venue
- Molecular and Cellular Endocrinology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 382
- Issue
- 1
- Pages
- 673-682
- ISSN
- 0303-7207 (ISSN-L)
- OpenAlex
- W2024203129
- Cited by
- 240
- References
- 12
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.